Results 211 to 220 of about 1,951,570 (332)

Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension

, 2022
Michael T. Eadon, Kerri L. Cavanaugh, Lori A. Orlando, David Christian, Hrishikesh Chakraborty, Kady-Ann Steen-Burrell, Peter Merrill, Janet Seo, Diane Hauser, Rajbir Singh, Cherry Beasley, Jyotsna Fuloria, Heather Kitzman, Alexander S. Parker, Michelle Ramos, Henry H. Ong, Erica N. Elwood, Sheryl Lynch, Sabrina Clermont, Emily J. Cicali, Petr Starostik, Victoria M. Pratt, Khoa A. Nguyen, Marc B. Rosenman, Neil Calman, Mimsie Robinson, Girish N. Nadkarni, Ebony Madden, Natalie Kucher, Simona Volpi, Paul Dexter, Todd C. Skaar, Julie A. Johnson, Rhonda M. Cooper‐DeHoff, Carol R. Horowitz   +34 more
openalex   +2 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Molecular pathogenesis of the schwannomatosis genes and genetic testing strategies. [PDF]

Fam Cancer
Smith MJ.
europepmc   +1 more source

Genomic susceptibility in practice: The regulatory trajectory of non-rare thrombophilia (NRT) genetic tests in the clinical management of venous thrombo-embolism (VTE)

, 2020
Mauro Turrini, Catherine Bourgain
openalex   +2 more sources

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Genetic testing for SCA27B in Korean multiple system atrophy. [PDF]

Brain
Laß J, Berselli M, Rioux D, Schaake S, Follett J, Bravo JE, Veit AD, Ronchetti W, Reiff SB, Huentelman MJ, Vuzman D, Bower P, Khurana V, Trinh J, Jeon B, Kim HJ, Farrer MJ.   +16 more
europepmc   +1 more source

Ethical, Legal, and Social Issues in Genetic Testing for Complex Genetic Diseases [PDF]

, 2011
Andrews, Lori, Zuiker, Erin Shaugnessy
core   +2 more sources

Genetic testing preferences in families containing multiple individuals with epilepsy [PDF]

, 2014
Janice O. Okeke, Virginia Tangel, Shawn T. Sorge, Dale C. Hesdorffer, Melodie R. Winawer, Jeff Goldsmith, Jo C. Phelan, Wendy K. Chung, Sara Shostak, Ruth Ottman   +9 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Not all information is equally important: informed consent to genetic testing for hereditary cancer. [PDF]

J Cancer Res Clin Oncol
Thomas P, Asmussen S, Klein K, Straub N, Stegen S, Kowalski C, Schüürhuis S, Speiser D, Feufel MA, Kendel F.   +9 more
europepmc   +1 more source